Participated · Seed · Mar 2026

Remi Health is building an alternative testing platform that supplies diagnostics infrastructure for healthcare providers, enabling the processing of large testing volumes quickly and reliably. Before seeking outside capital, the company had already processed more than 1 million tests, demonstrating meaningful product-market traction. Its solution addresses the growing workforce shortage in healthcare by automating and decentralizing parts of the diagnostics workflow. With fresh capital, management plans to scale operations across Europe’s fragmented healthcare systems, refine go-to-market execution, and improve unit economics. Founders Marvin Abert, Anthony Bielenstein, and André Lange emphasize operational reliability and resilience as key differentiators. The recent seed financing equips the team to move from proof-of-concept to large-scale deployment while continuing to educate generalist investors about the diagnostics space. The round’s completion allows leadership to pivot attention back from fundraising to product development and market expansion.

Participated · Equity · Feb 2025

HD operates HDmall, a marketplace that aggregates healthcare productized services—from health check-ups and vaccinations to surgeries—helping users find providers, compare options, and access installment payments. The platform lists over 30,000 SKUs from more than 2,500 hospitals and clinics, works with pharmaceutical partners, and serves roughly 400,000 paying customers across Thailand and Indonesia. HD reports about $100 million in annual gross transaction volume and aims to reach 5,000 healthcare providers and 600,000 patients by 2025. The company has built Jib AI, an AI chatbot trained on anonymized product, transaction, and chat-commerce data; roughly 60% of customer interactions are now handled by AI agents. Over the next 12 months HD plans to add order and refund processing, assisted checkouts, scheduling, EHR checking, medical information retrieval, and AI-powered asynchronous virtual care; over two years it plans to expand partnerships with insurers, pharma, employers, and educational institutions. HD also plans geographic expansion into Vietnam and Myanmar in addition to its existing Thailand and Indonesia operations. HD began as a marketplace for third-party healthcare and surgery services (HDmall) and is now building conversational AI tailored to the Southeast Asian healthcare customer journey. The company plans to train chatbots on its proprietary, anonymized transaction, chat, FAQ, and product catalog data gathered over years of operations. HD has worked with roughly 2,000 healthcare providers and reports that 30–40% of its transactions occur through chat commerce. Management aims to roll out a marketplace chatbot within three months and open the technology to third parties by the end of the year, creating a new SaaS revenue stream alongside marketplace commissions. The startup positions its product as vertical, domain-specific AI—“the Sierra AI of the Southeast Asian healthcare industry”—using local data as a competitive moat. During the COVID-19 period HD cut costs, and after the pandemic it moved toward profitability with roughly 2x year-on-year growth; the team accepted a moderate valuation to accelerate growth. HD operates a marketplace for outpatient services and a recently launched private-label surgery service (HDcare) that connects surgeons in private practice, cost-conscious patients, and vacant hospital operating rooms. The platform reports a supply of over 20 operating rooms across Thailand and Indonesia, potential access to more via 1,500 healthcare providers on its marketplace, and over 40 types of surgeries lined up. HD aims to scale HDcare to 200 surgeries performed per quarter by Q4 2023. The company monetizes via transaction cuts, listing fees from providers, and healthcare marketing solutions. Since its founding four years ago and based in Bangkok, HD has served around 250,000 patients and saw 7x sales growth during the pandemic, targeting 2–3x growth in the post-COVID years. HD positions itself as enabling offline medical providers with digital tools rather than competing with them.

Led · Series A · Feb 2024

Baseimmune develops a computational platform and proprietary deep-learning algorithm that predicts pathogen evolution and designs synthetic antigenic proteins intended to elicit broad protective immune responses. Its antigen designs integrate genomic, epidemiological, immunological, clinical and evolutionary data and can be applied across vaccine platforms including mRNA, DNA and viral vectors. The company aims to create cross-protective, “future-proof” vaccines engineered to be effective against current and emerging variants. With the new funding, Baseimmune plans to accelerate three preclinical vaccine programs targeting African swine fever, coronavirus, and malaria, expand its team, advance its technology, and increase the number of programs in development. Baseimmune was founded in 2019 by Joshua Blight, Ariane Gomes and Phillip Kemlo, who developed their approaches while at the Jenner Institute, University of Oxford. The company announced a Series A financing to support scaling and expedited delivery of vaccine candidates. Baseimmune uses an algorithm that combines genomic, epidemiological, immunological, clinical and evolutionary data to design synthetic 'pick and mix' antigens. Those antigens are intended to present the immune system with the components most likely to evoke strong protective responses. The designs can be fed into multiple vaccine platforms, including mRNA, DNA and viral vectors. The company grew out of Jenner Institute research by Dr Josh Blight and Dr Ariane Gomes, who teamed with software engineer Phillip Kemlo to build the platform. Baseimmune has partnered with DNA vaccine developer Touchlight to pursue a universal coronavirus vaccine and the team reports the algorithm predicted major SARS-CoV-2 variants such as Alpha and Delta from limited early data. It recently secured £3.5M (~$4.8M) to expand its pipeline, develop more vaccines in parallel, and broaden the diseases it can tackle. Baseimmune is a discovery‑phase biotech that uses big data, high-performance computing and machine learning to design complex antigen candidates and so-called "variant-proof" vaccines. Its platform combines pathogen and epidemiology datasets with biological expertise to generate antigens intended to protect against current and future strains. The company reports five antigens in various stages of development and collaborations that include a human vaccine candidate with Vaccitech and a malaria vaccine with Imperial College London. It has begun preclinical development of multiple candidates, including a universal COVID vaccine and a veterinary vaccine against African Swine Fever Virus (ASFV). Baseimmune says the new funding will enable further development of its platform and the start of preclinical lab work.

Led · Series A · Nov 2022

Turbine’s core product is a foundational virtual cell model that, together with a lab-in-the-loop data engine, creates digital twins of wet-lab assays. Researchers use these virtual assays through Turbine’s no-code Virtual Lab to run millions of in-silico experiments, identifying disease drivers and optimal therapeutic combinations far faster than physical labs allow. The platform has already supported more than 30 discovery programs for biopharma partners such as MSD (Merck & Co.), AstraZeneca and Bayer. Previously focused on oncology, the company is now expanding into immunology via a newly announced collaboration with an unnamed top-10 pharmaceutical firm that will supply proprietary immune-cell datasets. The fresh capital will fund the virtualization of additional assay types across discovery and translational medicine, further fine-tuning the platform to new tissues. Turbine is backed by prominent tech and life-sciences investors including Accel and MSD Global Health Innovation and operates from hubs in London and Budapest.

Participated · Series D · Sep 2019

Themis develops vaccines and immunomodulatory therapies using a proprietary measles vaccine vector platform. Its lead program, MV-CHIK, is Phase 3-ready and the company plans to initiate a pivotal global Phase 3 trial within months. The company is advancing other infectious-disease programs—Zika and Lassa Fever in Phase 1, and RSV, CMV, Norovirus and MERS in preclinical studies—and has an immuno-oncology portfolio launched in 2018 with the first therapeutic candidate entering clinical studies this year. Themis recently announced a collaboration with MSD to develop undisclosed vaccine candidates. The company has been funded to date by leading venture capital firms and prestigious non-dilutive grants. Themis closed a Series D financing totaling €40 million (USD 44 million) to support its clinical and pipeline expansion plans. Themis Bioscience develops vaccines and immunomodulating therapies for infectious diseases and cancer using a versatile technology platform for discovery, development and production. Its lead program, MV-CHIK, is a Chikungunya vaccine that received FDA fast track and EMA PRIME designations and produced compelling Phase 2 results published in The Lancet. The company planned a pivotal multi-center Phase 3 trial in Europe, the US and the Americas and will test a single-shot regimen, with clinical trial applications submitted in the second half of 2019 and initiation expected shortly thereafter. CEPI is providing up to US$21 million of non-dilutive capital with support from the EU’s Horizon 2020 programme to underwrite a significant portion of the Phase 3 trial and accelerate regulatory approval and access. Themis says the non-dilutive funding will extend resources for its earlier-stage vaccine and oncology programs. The company also highlights commercial manufacturing capabilities and intends to apply its platform to high-market-potential diseases both alone and with partners. Themis develops vaccines on a versatile platform, with programs targeting chikungunya, Zika, RSV, norovirus and CMV. Its most advanced candidate is a chikungunya vaccine that reported positive Phase 2 results and is being studied in 600 patients across the US, EU and South and Central America. The company presented favorable interim European study results at the ASTMH 2017 Annual Meeting. Themis intends to use recent financing to advance both clinical and pre-clinical vaccine development programs. Leadership emphasizes the platform’s potential to address major public‑health challenges and to move multiple candidates toward commercialization. The company highlights experience navigating complex clinical, regulatory and manufacturing issues as it advances its pipeline. Themis Bioscience is a Vienna, Austria-based biotechnology start-up focused on developing vaccines to prevent infectious diseases. Its lead product candidates are Dengue and Chikungunya fever vaccines built on a novel vaccine vector technology called Themaxyn™, which was initially developed at the Institut Pasteur in Paris. The company intends to use the funds from its recent financing to advance pre-clinical and clinical development activities for these candidates. Themis completed a €5m Series A financing to support these programs. Founded in 2009 and led by CEO Erich Tauber, the company previously received seed financing from the academic incubator INiTS, austria wirtschaftsservice (aws) and the Austrian Research Promotion Agency (FFG).